33.27 
0.44(1.31%) 10:59AM EDT - Nasdaq Real Time Price
| Prev Close: | 33.71 |
|---|
| Open: | 33.57 |
|---|
| Bid: | 33.27 x 600 |
|---|
| Ask: | 33.28 x 100 |
|---|
| 1y Target Est: | 36.85 |
|---|
| Beta: | 0.550 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 33.18 - 33.74 |
|---|
| 52wk Range: | 30.42 - 35.42 |
|---|
| Volume: | 193,516 |
|---|
| Avg Vol (3m): | 1,636,720 |
|---|
| Market Cap: | 16.63B |
|---|
| P/E (ttm): | 35.78 |
|---|
| EPS (ttm): | 0.93 |
|---|
| Div & Yield: | 0.26 (0.80%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- 1 Great Dividend You Can Buy Right Nowat Motley Fool(Sun, May 19)
- Zoetis' Apoquel for allergic dogs approved by FDAat theflyonthewall.com(Thu, May 16)
- FDA Approves APOQUEL® (oclacitinib tablet) to Control Itch and Inflammation in Allergic DogsBusiness Wire(Thu, May 16)
- ZOETIS INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 15)
- U.S. IPO market on track for best year since 2007at MarketWatch(Mon, May 13)
- This Family Member Is the Key to Big Investment Gainsat Motley Fool(Sun, May 12)
- ZOETIS INC. Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Tue, May 7)
- ING U.S. Kicks Off 2nd Biggest IPO of '13 in the Redat Fox Business(Thu, May 2)
- ING U.S. Unit Little Changed After IPO Prices Below Rangeat Bloomberg(Thu, May 2)
- An Animal of a Quarterat Motley Fool(Wed, May 1)
- ING U.S. Inc raises $1.3 billion in IPOat Reuters(Wed, May 1)
- Pfizer Sell-Off Was Too Much, Says Analystat Barrons.com(Wed, May 1)
- ING U.S. Unit’s IPO Led by ‘Unsung Heroes’ of AIG Bailoutat Bloomberg(Wed, May 1)
- Why Pfizer's Bad Outlook Doesn't Matterat Motley Fool(Tue, Apr 30)
- [$$] Pfizer Cuts Outlookat The Wall Street Journal(Tue, Apr 30)
Key Statistics
| Forward P/E (1 yr): | 20.54 |
|---|
| P/S (ttm): | 3.85 |
|---|
| Ex-Dividend Date: | 29-Apr-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 1.40 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.36 |
|---|
| Mean Recommendation*: | 2.2 |
|---|
| PEG Ratio (5 yr expected): | 1.56 |
|---|
Business Summary
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines. The company provides livestock products, including vaccines comprising Bovishield line, Improvac/Improvest, RespiSure li...
View More